Tetraphase Pharmaceuticals, Inc.
TTPH
TTPH was delisted on the 28th of July, 2020.
26 hedge funds and large institutions have $2.67M invested in Tetraphase Pharmaceuticals, Inc. in 2019 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 16 reducing their positions, and 43 closing their positions.
61% less funds holding
Funds holding: 66 → 26 (-40)
68% less capital invested
Capital invested by funds: $8.23M → $2.67M (-$5.56M)
75% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 16
93% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 43
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$214K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$10.8K |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$3.06K |
| 4 |
JP Morgan Chase
New York
|
+$1.65K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$13 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$403K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$396K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$265K |
| 4 |
RA
Royce & Associates
New York
|
-$254K |
| 5 |
Millennium Management
New York
|
-$251K |
TTPH Hedge Fund Activity: Q3 2019 in Review
26 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Tetraphase Pharmaceuticals, Inc. (TTPH) for Q3 2019, worth a combined $2.67M — down 68% from $8.23M a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of TTPH and 3 opened new positions — a net loss of 40 holders — while 16 trimmed existing stakes and 4 added.
The largest buyer was Renaissance Technologies, adding an estimated $214K. The largest seller was 683 Capital Management, exiting entirely with an estimated $403K sold.
- 26 institutional investors held Tetraphase Pharmaceuticals, Inc. (TTPH) as of Q3 2019, down from 66 in Q2 2019.
- Funds reported $2.67M of Tetraphase Pharmaceuticals, Inc. stock for Q3 2019, down 68% quarter-over-quarter.
- 3 funds opened new Tetraphase Pharmaceuticals, Inc. positions in Q3 2019 and 43 closed out, a net change of -40 holders.
- The largest Tetraphase Pharmaceuticals, Inc. buyer in Q3 2019 was Renaissance Technologies, an estimated $214K added.
- The largest Tetraphase Pharmaceuticals, Inc. seller in Q3 2019 was 683 Capital Management, an estimated $403K sold.
Based on aggregated 13F filings for Q3 2019.